Expect 20-25% upside in Cadila Healthcare: Parmar

9227 Investors following Cadila Health. Share this News with them.

0

Like this story, share it with millions of investors on M3

Expect 20-25% upside in Cadila Healthcare: Parmar

Ajay Parmar, Head-Institutional Research, Emkay Global Financial Services is of the view that one can expect 20-25% upside in Cadila Healthcare. It is one of the top five players in the domestic market. It is now moved from a pure domestic player to an international player.

Post your opinion here

 

0

Tweet

Share on Tumblr

Excerpts from Markets Midday on CNBC-TV18 Watch the full show » ALSO READ See previous views by Ajay Parmar See what other Experts & Brokerages are saying about Cadila Health See messages about Cadila Health Cadila Health BSE | NSE 13/02/12 Are Mutual Funds betting on Cadila Health?

Ajay Parmar , Head-Institutional Research, Emkay Global Financial Services is of the view that one can expect 20-25% upside in Cadila Healthcare .

Parmar told CNBC-TV18, "Cadila Healthcare basically is one of the top five players in the domestic market. It is now moved from a pure domestic player to an international player. It has a 37% exports and it is going at 24%. It has JV with Hospira, which can compensate for the loss which it can have from Pantoprazole. Currently it has a margin of 20%, likely to have a PAT CAGR of 25%. It has a RoC and RoE of 23% and 25% and it is valued currently at 11 times. This stock has not moved up much and being the top five players I believe there is lot of room for this particular scrip. I expect at least 20-25% increase from current market price."